167 related articles for article (PubMed ID: 10496940)
1. Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.
Wu TH; Gu XX
Infect Immun; 1999 Oct; 67(10):5508-13. PubMed ID: 10496940
[TBL] [Abstract][Full Text] [Related]
2. Investigation of non-typeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines.
Wu T; Chen J; Murphy TF; Green BA; Gu XX
Vaccine; 2005 Oct; 23(44):5177-85. PubMed ID: 16039021
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.
Gu XX; Tsai CM; Ueyama T; Barenkamp SJ; Robbins JB; Lim DJ
Infect Immun; 1996 Oct; 64(10):4047-53. PubMed ID: 8926067
[TBL] [Abstract][Full Text] [Related]
4. Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx.
Hirano T; Hou Y; Jiao X; Gu XX
FEMS Immunol Med Microbiol; 2003 Jan; 35(1):1-10. PubMed ID: 12589951
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.
Gu XX; Chen J; Barenkamp SJ; Robbins JB; Tsai CM; Lim DJ; Battey J
Infect Immun; 1998 May; 66(5):1891-7. PubMed ID: 9573066
[TBL] [Abstract][Full Text] [Related]
6. Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against Moraxella catarrhalis and nontypeable Haemophilus influenzae.
Singh S; Wilson JC; Cripps AW; Massa H; Ozberk V; Grice ID; Peak IR
Vaccine; 2020 Jan; 38(2):309-317. PubMed ID: 31668366
[TBL] [Abstract][Full Text] [Related]
7. Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates.
Hou Y; Gu XX
J Immunol; 2003 Apr; 170(8):4373-9. PubMed ID: 12682274
[TBL] [Abstract][Full Text] [Related]
8. Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.
Yu S; Gu XX
Infect Immun; 2007 Jun; 75(6):2974-80. PubMed ID: 17371852
[TBL] [Abstract][Full Text] [Related]
9. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas.
Gu XX; Sun J; Jin S; Barenkamp SJ; Lim DJ; Robbins JB; Battey J
Infect Immun; 1997 Nov; 65(11):4488-93. PubMed ID: 9353024
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.
Hu WG; Chen J; Battey JF; Gu XX
Infect Immun; 2000 Sep; 68(9):4980-5. PubMed ID: 10948114
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.
Yu S; Gu XX
Infect Immun; 2005 May; 73(5):2790-6. PubMed ID: 15845482
[TBL] [Abstract][Full Text] [Related]
12. Biological activities of antibodies elicited by lipooligosaccharide based-conjugate vaccines of nontypeable Haemophilus influenzae in an otitis media model.
Sun J; Chen J; Cheng Z; Robbins JB; Battey JF; Gu XX
Vaccine; 2000 Jan; 18(13):1264-72. PubMed ID: 10649628
[TBL] [Abstract][Full Text] [Related]
13. Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.
Ren D; Yu S; Gao S; Peng D; Petralia RS; Muszynski A; Carlson RW; Robbins JB; Tsai CM; Lim DJ; Gu XX
Vaccine; 2011 Jun; 29(25):4210-7. PubMed ID: 21501641
[TBL] [Abstract][Full Text] [Related]
14. Exploration of Moraxella catarrhalis outer membrane proteins, CD and UspA, as new carriers for lipooligosaccharide-based conjugates.
Hu WG; Berry J; Chen J; Gu XX
FEMS Immunol Med Microbiol; 2004 Jun; 41(2):109-15. PubMed ID: 15145454
[TBL] [Abstract][Full Text] [Related]
15. Protection against nontypeable Haemophilus influenzae challenges by mucosal vaccination with a detoxified lipooligosaccharide conjugate in two chinchilla models.
Hong W; Peng D; Rivera M; Gu XX
Microbes Infect; 2010 Jan; 12(1):11-8. PubMed ID: 19782149
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine.
Hirano T; Jiao X; Chen Z; Van Waes C; Gu XX
Immunol Lett; 2006 Nov; 107(2):131-9. PubMed ID: 17030407
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae.
Gu XX; Rudy SF; Chu C; McCullagh L; Kim HN; Chen J; Li J; Robbins JB; Van Waes C; Battey JF
Vaccine; 2003 May; 21(17-18):2107-14. PubMed ID: 12706701
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media.
Winter LE; Barenkamp SJ
Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28768669
[TBL] [Abstract][Full Text] [Related]
20. Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines.
Berenson CS; Murphy TF; Wrona CT; Sethi S
Infect Immun; 2005 May; 73(5):2728-35. PubMed ID: 15845475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
